Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind Placebo-Controlled Comparative Randomized Clinical Study of the Efficacy and Safety of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

NCT05732805 is registered in ClinicalTrials.gov with Biocad as lead sponsor.

NCT NCT05732805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05732805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind Placebo-Controlled Comparative Randomized Clinical Study of the Efficacy and Safety of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
Lead sponsor
Biocad
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 2, 2022
Completion date
July 31, 2025
Enrollment
270 (estimated)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, melanoma (skin), melanoma advanced, melanoma metastatic, melanoma stage iii, melanoma stage iv, melanoma unresectable